Activase® is proven to reduce disability at 90 days in patients treated within 3 hours of symptom onset 5

Explore the National Institute of Neurological Disorders and Stroke (NINDS) Trial

The NINDS Trial was a large, randomized, placebo-controlled trial of intravenous Activase versus placebo in patients with acute ischemic stroke (AIS) treated within 3 hours of stroke symptom onset and was carried out in 2 parts. 5,6

  • Part 1 (n=291) assessed changes in neurologic deficits 24 hours after the onset of strokea
  • Part 2 (n=333) assessed whether treatment with Activase resulted in sustained clinical benefit at 3 monthsb

aComplete resolution of neurologic deficit or an improvement from baseline NIHSS score of 4 or more were defined as early improvement 5
bScores of 95 or greater on the Barthel index, ≤1 on the NIHSS and the modified Rankin Scale, and 1 on the Glasgow Outcome Scale were considered to indicate a favorable outcome. 5

Trial Design




  • The NINDS Trial showed that Activase given within 3 hours of symptom onset of AIS reduced the incidence of disability among treated patients compared with placebo at 3 months. 5